Tests short radiation before CAR-T cell therapy for relapsed lymphoma
Tests short-course radiotherapy used as a bridge before CAR-T therapy in adults with relapsed lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT05514327
- Record updated
- 24 March 2026
- Original description
This is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphomaRead full original descriptionShow less
the Safety and Efficacy of Ultra-fraction Radiotherapy Bridging CART Cell Therapy in Relapsed/Refractory Diffuse Large b Cell Lymphoma
This is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphoma
Inclusion: Over than 18 years old; Histologically confirmed DLBCL(by central pathology review before enrolment); Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT; Measurable disease at time of enrollment (the maximum diameter of cross section ≥1.5cm); Life expectancy ≥12 weeks; Able to receive radiotherapy evaluated by specialist.
Exclusion: Prior radiation therapy within 1 year of infusion; Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion); Previous solid tumor within 3 years, previous or concurrent hematological malignancy; HIV positive patients, active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive ); Other conditions that the investigator may exclude due to risks or other possibilities; Severe organ dysfunction: left ventricle ejection fraction (LVEF) <40%; DLCO <40%; estimated glomerular filtration rate (eGFR)<30mL/min/1.73 m2; total bilirubin >3 ULN; Pregnant or nursing (lactating) women.